Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer in the world and the third or fourth leading cause of death (depending on where you do your research). Over 70% of cases are in Asian countries, predominantly due to high rates of endemic hepatitis infections.

This week, we climb a mountain in search of treatment options and advancements in this orphan cancer. Two trials are discussed: The first is HIMALAYA comparing durvalumab and tremelimumab versus the old incumbent sorafenib (tyrosine kinase inhibitor). Will immunotherapy take the reigns as the preferred agents? Our second study is Compassion-08, (Michael has an abundance of this). The trial is unique as it involves a first-in-class bispecific antibody targeting PD-1 and CTLA-4 (cadonilimab in combination with lenvatinib).

Interesting times ahead in the HCC space

Links to articles discussed in this episode (subscription may be required):

HIMALAYA: Link

COMPASSION-08: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.